GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ignyta Inc (NAS:RXDX) » Definitions » Price-to-Tangible-Book

Ignyta (Ignyta) Price-to-Tangible-Book : 17.23 (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ignyta Price-to-Tangible-Book?

As of today (2024-04-26), Ignyta's share price is $26.95. Ignyta's Tangible Book per Share of Sep. 2017 for the quarter that ended in Sep. 2017 was $1.56. Hence, Ignyta's Price to Tangible Book Ratio of today is 17.23.

The historical rank and industry rank for Ignyta's Price-to-Tangible-Book or its related term are showing as below:

RXDX's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.68
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Ignyta's share price is $26.95. Ignyta's Book Value per Sharefor the quarter that ended in Sep. 2017 was $1.56. Hence, Ignyta's P/B Ratio of today is 17.23.


Ignyta Price-to-Tangible-Book Historical Data

The historical data trend for Ignyta's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ignyta Price-to-Tangible-Book Chart

Ignyta Annual Data
Trend Aug12 Aug13 Dec14 Dec15 Dec16
Price-to-Tangible-Book
- - 2.40 3.19 2.33

Ignyta Quarterly Data
Nov12 Feb13 May13 Aug13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.17 2.33 6.20 5.07 7.83

Competitive Comparison of Ignyta's Price-to-Tangible-Book

For the Biotechnology subindustry, Ignyta's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ignyta's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ignyta's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Ignyta's Price-to-Tangible-Book falls into.



Ignyta Price-to-Tangible-Book Calculation

Ignyta's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2017 )
=26.95/1.564
=17.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Ignyta Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Ignyta's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Ignyta (Ignyta) Business Description

Traded in Other Exchanges
N/A
Address
Ignyta is an oncology biotechnology company. Its research is targeting tumor reduction and cancer treatment through both integrated therapeutic and companion diagnostics. The integrated therapeutic segment aims to discover, develop, and commercialize molecularly targeted therapies. The companion diagnostic segment aims to pair the discovered therapies with biomarker-based companion diagnostics to precisely identify, at the molecular level, patients likely to have good results. The company's portfolio includes compounds to treat adult patient populations for solid tumors, pediatric patients with advanced solid tumor malignancies, and patients with superficial and nodular basal cell carcinoma.
Executives
James L Freddo director 3115 MERRYFIELD ROW, SAN DIEGO CA 92121
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Pratik S Multani officer: Chief Medical Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Jonathan E Lim director, 10 percent owner, officer: President, CEO & Director 11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jacob Chacko officer: Chief Financial Officer C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Igor Bilinsky officer: GM, Immuno-Oncology/SVP Sp Ops C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Matthew Onaitis officer: General Counsel and Secretary C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Adrian Senderowicz officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024

Ignyta (Ignyta) Headlines

From GuruFocus

Steven Cohen Dives Deeper Into Health Care

By Graham Griffin Graham Griffin 03-23-2021